Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
147
resultados
Última actualización
27/07/2025 [06:55:00]
Resultados 100 a 125 de 147
Resumen de: WO2025122639A1
Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.
Resumen de: US2025185949A1
The present invention discloses a state-of-the-art non-invasive blood glucose monitoring system powered by radio frequency (RF) signals to determine glucose levels in the blood. The system consists of a sensor plate, which functions as an antenna, transmitting RF signals through the body and analyzing the reflection coefficient to detect changes in blood glucose concentration. A Voltage Standing Wave Ratio (VSWR) meter is integrated with the device to measure the reflection of the RF signal, which is indicative of the body's impedance mismatch due to glucose variations. The system incorporates a microcontroller, which processes the forward and reverse voltage signals obtained from the VSWR meter to calculate the reflection coefficient. In addition, a Bluetooth system is included for wireless data transmission to a secondary device, such as a smartphone or PC, where a specialized software application processes the VSWR data to estimate the blood glucose level through quadratic interpolation. The efficacy of the system is validated against standard glucometer readings, demonstrating its potential as a convenient and pain-free alternative for diabetes management and monitoring. The device's architecture and its components are designed to ensure user-friendly operation, precise measurements, and seamless integration into the user's lifestyle.
Resumen de: US2025189454A1
A Raman signal analysis device, which enables miniaturization of the device and noninvasive continuous monitoring of blood glucose level, includes a housing that forms an internal accommodation space therein; one or more light source units that are disposed within the housing and irradiate light onto a subject; a light receiving unit that obtains a Raman signal of light reflected or scattered from the subject using an optical filter array and an optical detection component array; and a processor configured to analyze biological information of the subject based on the Raman signal acquired by the light receiving unit.
Resumen de: US2025186485A1
A hydration system including a plurality of hydration compositions for improving vascular health is provided. A hydration system comprises a first hydration composition comprising protein in an amount from 0.25 mg to 1.5 mg per kilogram of the patient's weight, sodium, potassium, and one or more essential amino acids, a second hydration composition comprising protein in an amount from 0.25 mg to 1.5 mg per kilogram of the patient's weight, sodium, potassium, and a hydrogel, a pectin based additive, a starch, or a glycerin and a third hydration composition comprising protein in an amount from 0.25 mg to 1.5 mg per kilogram of the patient's weight and at least one of electrolytes or glucose, vitamins and minerals. The hydration compositions may be formulated for oral or enteral administration.
Resumen de: WO2025121504A1
The present invention relates to a blood glucose risk prediction and management system using blood glucose and personalized data. The blood glucose risk prediction and management system using blood glucose and personalized data includes: a user terminal which receives measurement data from a blood glucose measurement device and receives correlation factors as input; and a blood glucose management server that determines search conditions including two or more of a blood glucose measurement time, a personal state, and the correlation factors, and searches for a standard pattern among a plurality of standard patterns, compares the measurement data with the searched standard pattern to determine whether the user health state is abnormal, and if the user health state is determined to be abnormal, collects additional information and analyzes the user health state to determine whether the user health state is abnormal, and transmits an alarm for reporting the occurrence of an abnormal state to the user terminal.
Resumen de: US2025185959A1
Systems, methods and apparatus are provided, including one or more processors configured to detect a sensor calibration start event, determine outputs of one or more physiological models based on a plurality of parameters, the plurality of parameters including glucose data and insulin information, determine whether the outputs fall within a predetermined threshold, and in response to determining that the outputs fall within the predetermined threshold, execute a calibration routine.
Resumen de: US2025186695A1
The subject matter of this disclosure generally relates to a medical device system and related methodologies that leverage data associated with the use of a meal transaction application, such as an application for ordering food delivery. Data generated by the meal transaction application can be leveraged by a patient care system or application for purposes of diet or calorie logging. Alternatively or additionally, the meal transaction data can be leveraged for purposes of controlling the administration of therapy by a medication delivery system, such as an insulin infusion pump.
Resumen de: US2025186696A1
Disclosed herein are methods for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, a smartphone or other remote consumer electronic device and/or a dedicated remote controller for the infusion pump. In order to ensure reliable communication of data, more than one component in a system can be capable of relaying data to another component.
Resumen de: US2025185950A1
A system and method for wireless transmission of glucose data. According to an embodiment of the present disclosure, there is provided a system, including: a glucose sensor; a beacon transmitter; and a processing circuit connected to the glucose sensor and the beacon transmitter, the processing circuit being configured to transmit a data packet, the data packet including measurement data including a measurement value, the measurement value being based on a glucose measurement.
Resumen de: US2025185951A1
In response to insertion of a continuous glucose monitoring (CGM) sensor into the skin of user, a CGM system compares an identifier of the sensor to any previously-stored identifiers of previously-inserted sensors. If the identifier does not match a previously-stored identifier, indicating a newly-inserted sensor, the identifier and a time stamp are stored and CGM may begin. Upon removal of the sensor, a removal time stamp is stored. If the identifier of an inserted sensor matches a previously-stored identifier, indicating a reinserted sensor, a reinsertion time is obtained and an elapsed removal time is checked to determine whether it exceeds a maximum removal time limit. If it does, CGM is halted. If it does not, CGM may continue with the reinserted sensor. Methods of tracking insertion and removal times of a CGM sensor are also provided, as are other aspects.
Resumen de: US2025191743A1
Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.
Resumen de: EP4566644A2
The present disclosure relates to a drug-delivery device that is attachable to an infusion set hub that has been pre-inserted into a patient's body. The pre-inserted infusion set hub may be configured to deliver a primary drug such as insulin or an insulin analog. The drug-delivery device may deliver a secondary drug such as a glucagon, an NSAID, or another type of insulin or insulin analog through a cannula of the infusion hub.
Resumen de: WO2025117463A1
Disclosed herein are systems and methods for closed loop and/or partial and/or hybrid closed loop therapy that can provide adaptive personal profiles for when glucose levels are not available and/or unreliable from a continuous glucose monitor (CGM), such as, for example, during a warmup period of the CGM sensor. The profile can include temporary delivery profile such as a CGM warmup profile that is activated specifically for the particular scenario and is designed to minimize the risk of blood glucose fluctuations until the glucose levels are available and reliable, such as when the CGM sensor is warmup up and closed loop therapy based on the sensor can be activated.
Resumen de: WO2025117799A1
Embodiments described herein gradually shift a basal rate pattern for a user in time when the time on an insulin pump is changed and use glucose levels from a CGM sensor to coordinate the shift in the basal pattern with the user's actual glucose response to the changing parameters to safely transition the timing of the basal pattern as quickly as possible.
Resumen de: WO2025117512A1
A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.
Resumen de: WO2025116762A1
The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of sensors for non-invasively checking a person's blood glucose concentration, as well as in the creation of socially-oriented systems for the early diagnosis of diabetes and associated diseases. The aim of the invention is to improve the operational efficiency of a sensor for a wrist-worn device for non-invasively checking a person's blood glucose concentration by reducing the operational energy consumption of the sensor by virtue of the shape of the inner surface of a rim. The technical result of the invention is that of reducing the operational energy consumption of the sensor. This reduction is achieved by virtue of the shape of the inner surface of a rim, which results in an increase in the amount of light reflected from the arm, and specifically from an artery and other vessels in the arm, and impinging on a light receiver.
Resumen de: WO2025116086A1
The present invention relates to technology for measuring blood glucose and glycated hemoglobin using a non-invasive PPG sensor and, more specifically, to a method and an apparatus for measuring blood glucose and glycated hemoglobin by using artificial intelligence technology in which pulse wave signals of a measurer are sensed using a PPG (pulse wave) sensor and analyzed by a machine learning algorithm to estimate blood glucose and glycated hemoglobin levels.
Resumen de: US2025176868A1
A method of calculating at least one physiological parameter using a reticulocyte production index (RPI) value can include: measuring a plurality of first glucose levels over a first time period; measuring a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; measuring the RPI value; calculating a red blood cell elimination constant (kage) based on the RPI value; and calculating the at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (kgly), a red blood cell generation rate constant (kgen), and an apparent glycation constant (K), based on (1) the plurality of first glucose levels, (2) the first HbA1c level, and (3) the kage. Further, one or more related analyses (e.g., personalized-target glucose range, personalized-target average glucose, cHbA1c, and the like) can be estimated and/or adjusted based on the at least one physiological parameter.
Resumen de: US2025176865A1
The proposed invention relates to a method of determining a blood glucose level of a user. The method comprises obtaining, by a Photoplethysmography (PPG) sensor (302), raw data related to pulsations of a user. The raw data is filtered by a Data Signal Processing (DSP) filter to obtain derived variables related to variations in blood viscosity. The raw data is further processed by a probabilistic model to obtain secondary variables related to operating conditions of a circulatory and respiratory system of the user. Readings of the PPG sensor (302) are obtained by a microcontroller (306). The readings of the PPG sensor (302) indicates intensity values of reflections of light transmitted by the PPG sensor onto a blood vessel of the user. The readings of the PPG sensor (302) are processed based on the derived variables and the secondary variables to determine a blood glucose level of the user.
Resumen de: US2025177649A1
A portable insulin pump can integrate and display data from a continuous glucose monitor (CGM) to allow a user to more readily determine whether any interaction with the pump is necessary. Data from the CGM can automatically be transmitted to the pump and can be displayed for user analysis or automatically analyzed to present recommendations to the user based on combined data from the CGM and the pump.
Resumen de: US2025180540A1
A blood glucose measurement device having a display, includes a housing having one or more openings on one side, one or more contact electrodes configured to electrically coupled to a sensor strip inserted into the housing through the one or more openings, one or more control buttons configured to turn on the blood glucose measurement device, and one or more processors configured to control a first execution screen to be displayed in response to receiving a first signal by the one or more contact electrodes and, display a second execution screen in response to receiving a second signal by the one or more control buttons.
Resumen de: US2025180505A1
A glucose biosensor encasement includes a first membrane and a second membrane. The first membrane has a first interlocking segment. The second membrane has a second interlocking segment cooperating with the first interlocking segment of the first membrane to provide a cavity between the first membrane and the second membrane configured to receive a glucose sensor. At least one of the first membrane and the second membrane comprises a semi-permeable portion configured to regulate diffusion characteristics of glucose through the membrane to realize a sensitivity for a sensor in the cavity. A method is also provided.
Resumen de: US2025176870A1
A device for determining a glucose concentration in an anterior chamber of a user's eye includes a VCSEL which emits laser light, and an optical element for influencing the laser light and/or an emergent light. The VCSEL and the optical element are configured such that the laser light enters the anterior chamber of the eye. The emergent light from the anterior chamber penetrates into the VCSEL. The device further includes an analysis unit that analyses a resulting self-mixing interference within the VCSEL to determine the glucose concentration.
Resumen de: US2025182875A1
An apparatus comprising a controller. The controller includes an input/output (I/O) module and a rule module. The I/O module is configured to present a question for a patient when communicatively coupled to a user interface and receive patient information in response to the question via the user interface. The rule module is configured to apply a rule to the patient information and generate a suggested insulin pump setting from application of the rule. Other devices, systems, and methods are disclosed.
Nº publicación: US2025182874A1 05/06/2025
Solicitante:
UNIV OF VIRGINIA PATENT FOUNDATION [US]
UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Resumen de: US2025182874A1
An insulin delivery supervisor (IDS) with a safety analysis and supervision function that can reside between the insulin request and the insulin delivery and can intercept any excessive insulin requests before the insulin was delivered. The IDS can be implemented in any system based on insulin pump or pen and will work with either SMBG or CGM modes of blood glucose monitoring.
BOPI
Sede Electrónica
